WuXi acquires manufacturing facility in Couvet, Switzerland. The advisors
WuXi STA, a subsidiary of WuXi AppTec, a pharmaceutical development and manufacturing capability and technology platform company, whose shares are listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange, completed the acquisition of a tablet & capsule manufacturing and packaging facility in Couvet, Switzerland, from Bristol Myers Squibb.
The advisors
Lenz & Staehelin acted as Swiss legal advisor to WuXi STA in this transaction. The team was led by partner Andreas Rötheli (co-head corporate and m&a, pictured) and included associates Ralph Kaufmann and Roman Graf (corporate and m&a), Giulia Neri–Castracane and Cécile Vulliemin (real estate), Sevan Antreasyan (ip, regulatory & life sciences), Sandrine Kreiner, Prisca Cattaneo and Bertrand Donzé (employment), and Benoît Biedermann (tax).
DLA Piper Hong Kong and New York acted as lead counsel to WuXi STA in this transaction.
The acquisition included the site’s operations and assets, among which the plant and equipment, as well as the workforce with technical capabilities and expertise.
